NOVEL GENETIC ABNORMALITY RELATED TO ACUTE LYMPHOBLASTIC LEUKEMIA, AND USES THEREOF

摘要

The present invention addresses the problem of discovering a novel genetic abnormality, which is useful for the determination of treatment strategies or prognostic prediction of acute lymphoblastic leukemia, and contributing to the improvement of treatment outcomes. A genetic abnormality characterized by the formation of a fusion gene comprising the MEF2D gene and the BCL9 gene has been discovered from recurrent childhood acute lymphoblastic leukemia patients. This genetic abnormality will serve as a new indicator when determining treatment strategies.